INS and metabolic dysfunction-associated steatotic liver disease: In the absence of approved pharmacological therapies for NAFLD treatment, prior to the accelerated approval of Resmetirom last year [90,91], hypocaloric diets alone or in combination with incremental physical activity programs were effective methods for achieving consistent weight loss and improving hepatic steatosis and insulin sensitivity, and were therefore recommended by European and American guidelines as first-line interventions for the prevention and treatment of NAFLD [92,93].